Zhejiang centralized procurement 400 million market pattern reshapes 22 varieties "going to the examination room"

　　Recently, a notice on the procurement data related to the scope of the first batch of continuous and third batch of drug collections by public medical institutions in Zhejiang Province (hereinafter referred to as the volume report notice) has been circulated in the industry
.
20 chemical drugs such as lansoprazole and the first batch of 2 varieties (amoxicillin-clavulanate potassium, ceftizoxime) that have not renewed their contracts appeared in the official list of reported varieties.
The above 22 varieties will be listed in Zhejiang Province in 2021.
The terminal sales scale of public hospitals is close to 400 million yuan
.
According to the speculation of the release time of the "Notice of Reported Volume", the time for the opening of bids for the third batch of centralized procurement is expected to be moved forward
.
The situation of "only the one with the lowest price is selected" is no longer the case, and the advantages of the "two-envelope" model are highlighted.
Since 2020, provincial/provincial alliance collections have blossomed everywhere, and localities have successively launched injections, insulin, and antibacterial drugs according to their actual conditions.
Various types of special centralized procurement, procurement rules, selection modes, etc.
also have similarities and differences
.
As far as Zhejiang Province is concerned, its innovation is that the products included in the purchase with quantity are divided into Group A (original drugs or reference preparations, generic drugs that have passed the consistency evaluation) and Group B (other generic drugs), that is, " "Double-envelope" mode, if any one of the two groups A and B fails, then 50% of the agreed purchase amount of this group will be merged into the agreed purchase amount of the other group, and the remaining 50% will be used as the remaining amount other than the agreed purchase amount
.
This is a good signal for some selected varieties and unselected varieties
.
● In terms of the agreed procurement volume - each variety is based on 60% of the total annual drug consumption of all public medical institutions in the province in 2021 , which is divided into three situations: (1) Both groups are selected: the agreed procurement volume of groups A and B are respectively Determined according to the procurement share of all public medical institutions in the province in 2021 (the maximum and minimum agreed purchase volume are 50% and 10% of the total annual drug consumption of the variety respectively); (2) Any of the two groups A and B will not be selected.
Drugs: 50% of the agreed purchase amount of this group is merged into another group, and the remaining 50% is used as the remaining amount other than the agreed purchase amount; (3) Either group A or B will only receive 50% of the original agreed purchase amount: Half of the other 50% of the original agreed purchase amount of this group is merged into another group, and the remaining half is used as the remaining consumption beyond the agreed purchase amount
.
● In terms of procurement rules - the third batch of technical review is roughly the same as the second batch, with a total of 6 indicators, including clinical efficacy, quality reliability, clinical use safety, brand recognition, packaging quality and convenience, service reputation,
etc.
Technical evaluation score table According to the expert's score, the highest and lowest scores are removed, and the average score (rounded to 2 decimal places) is taken as the expert evaluation result
.
The A and B groups of each variety are ranked from high to low respectively.
If the last place has the same score, they will enter the price review stage together
.
Comparing with the second batch of centralized procurement, the price evaluation part is similar to that of the shortlisted enterprises .
It is divided into two cases: the number of declared enterprises = 1, and the number of declared enterprises ≥ 2.
The specific details of the proposed selection are shown in the following figure: Price evaluation to be selected Detailed Rules The third batch of centralized procurement in Zhejiang Province will follow the "two-envelope" mode of combined technical review and price review for centralized procurement
.
It can be seen from the technical evaluation indicators that the scores of non-price factors such as efficacy, quality and safety account for a relatively high proportion, which reflects the synchronization requirements for drug quality and price
.
Under the "two-envelope" model, in addition to controlling product prices, enterprises should also pay more attention to the cultivation of "internal skills" such as their own product advantages and technical indicators
.
In addition, it is worth noting that the "Notice of Reporting Volume" requires medical institutions to scientifically and accurately report the volume according to factors such as changes in the drug structure and adjustment of medical insurance payment policies.
Yes, the system will give an early warning prompt
.
400 million market reshuffle! Rabeprazole, cefotaxime.
.
.
Product pattern reshaping The annual provincial-level transport volume in each province has become normalized
.
Looking back at the first two batches of drugs purchased in Zhejiang Province, the first batch plans to include 8 varieties and 16 specifications, and finally 10 drugs are selected; the second batch plans to include 17 varieties and 34 varieties, and finally 21 drugs are selected.

.
List of the first batch of selected drugs for centralized procurement in Zhejiang Province Selected list of the second batch of drugs for centralized procurement in Zhejiang Province Source: Official website of Zhejiang Provincial Pharmaceutical Equipment Purchasing Center Hospital terminal sales rose 45.
18%
.
There are two selected companies.
Among them, Eisai (original research) is still strong, and its market share will remain above 90% from 2021; Shuanghe Pharmaceutical (Hainan) has grown steadily, with a market share of 2% to 3% in the past two years.
This product ranks third in the TOP20 brand pattern
.
In 2021, the sales of cefotaxime sodium for injection in public hospital terminals in Zhejiang Province will increase by 70.
27%.
Guangdong Jincheng Jinsu and Shandong Luoxin will use the advantages of centralized procurement to achieve "zero breakthrough" in Q1 market share in 2022 ”, the combined market share of the two exceeds 16%
.
Another best-selling product, desloratadine citrate tablets, will increase in sales by 34.
31% in public hospital terminals in Zhejiang Province in 2021.
This product is the exclusive product of Yangtze River Guangzhou Hairui Pharmaceutical; Annual sales are expected to hit a new record high
.
Haisco has two products selected in the second batch of centralized procurement.
Among them, the sales of nalmefene hydrochloride injection in public hospital terminals in Zhejiang Province will increase by 8.
25% in 2021, and Haisco's market share in this product will be less than 8%.
, is expected to reverse the trend after the election
.
In recent years, the terminal sales scale of public hospitals in Zhejiang Province (unit: 100 million yuan) Source: MINET.
com’s competition pattern of public hospital terminals in key provinces and cities.
MINET.
com data shows that in key provinces and cities, the sales of public hospital terminals in Zhejiang Province in 2020 and 2021 More than 10 billion yuan on average
.
At present, the two batches of Zhejiang Province's centralized procurement have included 31 drugs, and the total sales in the province's public hospital terminals in 2021 will be about 400 million yuan
.
The third batch of centralized procurement is on the way, and 22 varieties such as lansoprazole and leuprolide are planned to be included in the timeline of drug centralized procurement in Zhejiang Province in recent years.
The first two batches are released in October every year.
The list of proposed varieties will be announced in December, and the results will be announced in January next year
.
The third batch of centralized procurement released the "Notice of Quantity Report" in late August this year.
It can be seen that the bid opening date of this batch of centralized procurement is expected to move forward.
This move may be enough to prepare for the eighth batch of national procurement and the 2022 national talks.
time
.
It was learned from the "Notice of Reported Volume" that 22 chemical drugs such as lansoprazole and leuprolide (including the first batch of unrenewed varieties, the same below) are planned to be included in the third batch of centralized drug procurement in Zhejiang Province.
10 biological drugs, including growth hormone, have not yet appeared in this batch of collected and reported quantities
.
The list of the third batch of varieties collected in Zhejiang Province The data from Minet.
com shows that the sales scale of 22 varieties in public hospitals in Zhejiang Province will be close to 400 million yuan in 2021; from the perspective of treatment categories, digestive system and metabolic drugs occupy 10 seats , 3 cardiovascular and cerebrovascular drugs and systemic anti-infective drugs, 2 anti- tumor and immunomodulatory drugs, and 2 nervous system drugs
.
Over-evaluation of products to be included in the third batch of centralized collection (including approval of new registration classification) , except for amoxicillin sodium and clavulanate potassium for injection, triptorelin acetate injection and lactulose oral solution, most of the varieties to be included in this batch of centralized collection have not yet been reviewed by enterprises
.
In fact, the provincial/inter-provincial alliance collection is more like a supplement after the national purchase, the "successor" of market resource redistribution; the implementation and promotion of the provincial/inter-provincial alliance collection reflects the national Adhere to the guiding principles of purchasing with quantity , ensuring quality, promoting innovation, stabilizing supply, ensuring clinical use, and setting bidding rules for specific varieties and competitive landscapes”
.
Source: Minet database, official website of Zhejiang Provincial Pharmaceutical Equipment Purchasing Center, etc.
Note: The database of chemical drug terminal competition in public hospitals in key provinces and cities of Minet is based on the chemical drug procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities.
, a sample province and city sample hospital database for continuous monitoring of all categories of chemical drugs; the above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of August 23.
If there are any omissions, please correct me! "Only the one with the lowest price is selected" is no longer the case, and the advantage of the "two-envelope" model highlights the 400 million market reshuffle of pharmaceutical companies ! Rabeprazole, cefotaxime.
.
.
The product pattern reshapes the hospital　　The third batch of centralized procurement is on the way, and 22 varieties such as lansoprazole and leuprolide are planned to be included in tumor procurement